VPN Plus+ ExclusiveCompounding benefits through medication form optionsFebruary 14, 2024Not only do the pet and owner benefit from the use of a compounding pharmacy, but the veterinary practice can, as well. When appropriate, compounding provides veterinarians and their teams with an opportunity to offer a solution for the pet owner to enhance the human-animal bond versus causing stress and anxiety for the pet and the owner. Compounding can also provide veterinary practices with innovative ways to provide additional services and increase customer loyalty.
SPONSORED CONTENTOne dose protects for 12 months.One ProHeart® 12 (moxidectin) injection puts compliance in your control. + Get started
Nixing 'compounded' medication problemsSeptember 18, 2023With the growth of 503B-manufactured veterinary drugs, there has been an increase in the number of compounded medications available in a range of “standard” dosage offerings appropriate for animal use.
FDA updates compounding guidelines for vetsDecember 7, 2022This past summer, the Food and Drug Administration (FDA) issued a new Guidance for Industry (GFI) that will take effect in April 2023, affecting how compounding pharmacies fill veterinary prescriptions. Called GFI #256, the guidance is intended to encourage the use of FDA-approved drugs by veterinary professionals and control which bulk substances are used to create compounded medications.
The why and when to compound medicationsMarch 22, 2022Do your doctors freeze when you say, “Why don’t you have it compounded?”
Best practices for storing pharmaceuticalsNovember 15, 2021Out of necessity, many drugs used in veterinary medicine are available in multiple formulations. The sheer quantity of species treated in this profession requires a wide range of doses and formulations be available for our patients.
What does 503B compounding mean for the future of veterinary medicine?April 3, 2019Modern compounding—often referred to as 503A—is a niche business, providing patient-specific formulations to satisfy individual needs. Because commercially available drugs are marketed almost exclusively for humans, compounding has become an essential resource for veterinary medicine. Veterinarians often depend on 503A pharmacies to provide preparations at lower concentrations and in more palatable dosage forms to optimize treatment for their patients. However, without proper management and regulations, 503A compounding can potentially be detrimental. Presently, 503A pharmacies are not required to adhere to Current Good Manufacturing Practice (cGMP) objectives put forth by the U.S. Food and Drug Administration (FDA) to ensure pharmaceuticals achieve a specified standard of safety. The quality of products produced in a 503A facility depend on the pharmacy's voluntary conformance with cGMP, which can be substantially cost-prohibitive, requiring anywhere from $50,000 to $100,000-plus of investment for a single formulation. Testing on raw materials and finished products may be performed to an extent depending on the facility, but the data are often incomplete, testing only one or two factors while omitting others that would affect the product's overall quality. The variability of cGMP compliance from pharmacy to pharmacy paves the way for omissions in procedures that can lead to patient harm. …
